830 Winter Street,
Waltham, Maine 02451
Praecis Pharmaceuticals, Inc. is a biopharmaceutical company focused on utilizing its proprietary technologies for the discovery and development of novel compounds that have the potential to address unmet medical needs or improve existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkinâ€™s lymphoma and solid tumors, an innovative drug discovery technology, DirectSelectâ„¢, which enables the generation and practical use of ultra-large libraries for the discovery of orally active compounds for drug development, and a research and development program aimed at identifying one or more selective S1P-1 agonist compounds to advance into clinical testing.
Praecis Pharmaceuticals was acquired by GlaxoSmithKline on February 16, 2007.
Join Mergr to view all 126 acquisitions of life science companies in 2007, including 26 acquisitions by private equity firms, and 100 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2007. The largest life science acquisition in 2007 was Organon BioSciences N.V. - which was acquired by Schering-Plough for $12.4B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Praecis Pharmaceuticals.
No obligation. Cancel anytime.